CoChat

Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses

Open access
Tampi, Rajesh R., Tampi, Deena J., Balachandran, Silpa, Srinivasan, Shilpa · 2016 · Therapeutic Advances in Chronic Disease

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background: The purpose of this review is to evaluate the data on the use of antipsychotics in individuals with dementia from meta-analyses. Methods: We performed a literature search of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases through 30 November, 2015 using the following keywords: ‘antipsychotics’, ‘dementia’ and ‘meta-analysis’. The search was not restricted by the age of the patients or the language of the study. However, in the final analysis we only included studies involving patients that were published in English language journals or had official English translations. In addition, we reviewed the bibliographic databases of published articles for additional studies. Results: This systematic review of the literature identified a total of 16 meta-analyses that evaluated the use of antipsychotics in individuals with dementia. Overall, 12 meta-analyses evaluated the efficacy of antipsychotics among individuals with dementia. Of these, eight also assessed adverse effects. A further two studies evaluated the adverse effects of antipsychotics (i.e. death). A total of two meta-analyses evaluated the discontinuation of antipsychotics in individuals with dementia. Overall, three meta-analyses were conducted in individuals with Alzheimer’s disease (AD) whereas one focused on individuals with Lewy Body Dementia (LBD). The rest of the 12 meta-analyses included individuals with dementia. Conclusions: Antipsychotics have demonstrated modest efficacy in treating psychosis, aggression and agitation in individuals with dementia. Their use in individuals with dementia is often limited by their adverse effect profile. The use of antipsychotics should be reserved for severe symptoms that have failed to respond adequately to nonpharmacological management strategies.

Overview

Integrity signals

Registry

Crossref · 10.1177/2040622316658463

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 51 · Cited by 267

Research works printed but not linked: 5

  1. Ballard C., 2006, Cochrane Database Syst Rev, 1, CD003476
  2. Cheung G., 2011, NZ Med J, 124, 39
  3. Declercq T., 2013, Cochrane Database Syst Rev, 3, CD007726
  4. Kirchner V., 2001, Cochrane Database Syst Rev, 3, CD000464
  5. Seitz D., 2011, Cochrane Database Syst Rev, 2, CD008191

Metadata

Authors
Tampi, R. R., Tampi, D. J., Balachandran, S., & Srinivasan, S.
Affiliations
  • MetroHealth (US)
  • Saint Francis Hospital & Medical Center (US)
  • University of South Carolina (US)
Corresponding author
Tampi, Rajesh R.
Venue
Therapeutic Advances in Chronic Disease
Published
2016-07-31
Volume
7
Issue
5
Pages
229-245
ISSN
  • 2040-6223 (ISSN-L)
  • 2040-6231
OpenAlex
W2468352757
Cited by
267
References
51
Citations by year
2026: 23 · 2025: 31 · 2024: 26 · 2023: 37 · 2022: 32 · 2021: 45 · 2020: 29 · 2019: 25 · 2018: 13 · 2017: 4 · 2016: 1
FWCI
2.05
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Chronic Disease (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
antipsychotic drugs, dementia, Alzheimer's disease, dementia with Lewy bodies, psychosis, aggression, agitation, adverse effects, drug efficacy, non-pharmacological treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. https://app.cochat.ai/papers/10.1177/2040622316658463
The paper
Tampi, R. R., Tampi, D. J., Balachandran, S., & Srinivasan, S. (2016). Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/2040622316658463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.